Pharmacyclics of Sunnyvale, CA, has received regulatory approvalin the U.K. for its Gadolite oral MRI contrast agent, which isindicated for diagnosing pelvic and abdominal disorders. Gadolitewill be marketed in the U.K. and the rest of Europe by E-Z-EMof
Pharmacyclics of Sunnyvale, CA, has received regulatory approvalin the U.K. for its Gadolite oral MRI contrast agent, which isindicated for diagnosing pelvic and abdominal disorders. Gadolitewill be marketed in the U.K. and the rest of Europe by E-Z-EMof Westbury, NY, under a deal between the two companies announcedthis month. E-Z-EM will file marketing applications for Gadolitein additional European countries under the European Union's mutualrecognition process.
E-Z-EM also has rights to Gadolite in the U.S., Canada, andMexico. A new drug application for Gadolite was filed with theFood and Drug Administration in September, according to the companies.Gadolite is manufactured by Glaxo Wellcome.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.